Story perspectives

Bayer Boosts Pharma Research in China; GSK, Eli Lilly Progress

6/28/2025

37 6

Summary

Story summary

Bayer is strengthening its collaboration with Tsinghua University to boost pharmaceutical research in China, targeting innovative drug discovery for various diseases. In Europe, GSK's linerixibat is under EMA review for treating cholestatic pruritus. Meanwhile, Eli Lilly's diabetes treatments, orforglipron and efsitora alfa, are showing encouraging phase III results, and Ozempic may soon be recognized for its benefits in peripheral arterial disease.

1 of 1

Story summary

Bayer is strengthening its collaboration with Tsinghua University to boost pharmaceutical research in China, targeting innovative drug discovery for various diseases. In Europe, GSK's linerixibat is under EMA review for treating cholestatic pruritus. Meanwhile, Eli Lilly's diabetes treatments, orforglipron and efsitora alfa, are showing encouraging phase III results, and Ozempic may soon be recognized for its benefits in peripheral arterial disease.